Business Description
Imugene Ltd
ISIN : AU000000IMU9
Description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 61.15 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -71 | |||||
| 3-Year EPS without NRI Growth Rate | -71 | |||||
| 3-Year FCF Growth Rate | -58.7 | |||||
| 3-Year Book Growth Rate | 7.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.66 | |||||
| 9-Day RSI | 33.74 | |||||
| 14-Day RSI | 37.91 | |||||
| 6-1 Month Momentum % | -24.3 | |||||
| 12-1 Month Momentum % | -57.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.86 | |||||
| Quick Ratio | 3.86 | |||||
| Cash Ratio | 3.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.8 | |||||
| Shareholder Yield % | -18.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -89.32 | |||||
| ROA % | -77.57 | |||||
| ROIC % | -233.12 | |||||
| ROC (Joel Greenblatt) % | -1703.56 | |||||
| ROCE % | -85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.23 | |||||
| Price-to-Tangible-Book | 2.23 | |||||
| EV-to-EBIT | -1.21 | |||||
| EV-to-Forward-EBIT | -10.28 | |||||
| EV-to-EBITDA | -1.21 | |||||
| EV-to-Forward-EBITDA | -8.39 | |||||
| EV-to-FCF | -1.64 | |||||
| Price-to-Net-Current-Asset-Value | 2.25 | |||||
| Price-to-Net-Cash | 2.25 | |||||
| Earnings Yield (Greenblatt) % | -82.64 | |||||
| FCF Yield % | -43.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IUGNF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imugene Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.014 | ||
| Beta | 2.75 | ||
| Volatility % | 60.69 | ||
| 14-Day RSI | 37.91 | ||
| 14-Day ATR ($) | 0.003621 | ||
| 20-Day SMA ($) | 0.025825 | ||
| 12-1 Month Momentum % | -57.29 | ||
| 52-Week Range ($) | 0.02 - 0.105 | ||
| Shares Outstanding (Mil) | 7,567.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imugene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imugene Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imugene Ltd Frequently Asked Questions
What is Imugene Ltd(IUGNF)'s stock price today?
The current price of IUGNF is $0.02. The 52 week high of IUGNF is $0.11 and 52 week low is $0.02.
When is next earnings date of Imugene Ltd(IUGNF)?
The next earnings date of Imugene Ltd(IUGNF) is .
Does Imugene Ltd(IUGNF) pay dividends? If so, how much?
Imugene Ltd(IUGNF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers